W ith the emergence of small molecule screening as a powerful research tool in biology, biomolecular screening has arrived in the laboratories of academe. More and more, researchers in universities and hospital research institutes are recognizing the power of small molecules as probes of biochemical and biological systems. At McMaster University in Hamilton, Canada, we have established a state-of-the-art small molecule screening laboratory that became fully operational a little more than a year ago (http:// hts.mcmaster.ca). It is with considerable enthusiasm, as the founding director of that laboratory, that I offer the following perspectives on screening in an academic setting and on my own experiences in setting up such a facility.
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Since the establishment of the first academic screening operations, including, for example, that of the Harvard Institute of Chemistry and Cell Biology in the late 1990s, there has been a groundswell of interest among academic researchers in highthroughput screening (HTS). Today, biological researchers in most research-intensive academic institutions are, at the very least, considering the establishment of capabilities and a presence in small molecule screening to fuel research activities in the emerging field of chemical biology. Nevertheless, the implementation of a reasonably capable screening facility with its associated liquid-handling, instrumentation, compound, and information management systems is a complex, costly, and energetic undertaking.
In setting up a state-of-the-art screening laboratory, it has been instructive for me to reflect on how advances in HTS in the private sector have exerted recent influence on research directions in biological research at universities and research institutes. This trend contrasts with the conventional academic view of innovation that has emerging technology moving from university to industry. Advances in biological research have, of course, been among the most celebrated university-based innovations. The once purely academic pursuits of biological chemistry and cell biology have slowly but firmly established themselves in the research paradigm of formerly chemistry-centered pharma, beginning with revolutionary advances in molecular biology in the late 1970s. It is perhaps ironic, if not remarkable, then, that similarly revolutionary progress made by high-throughput screeners in the pharmaceutical sector has affected the technology now available to chemical biologists in academe.
Equipped with robust robotics, information systems, and wellestablished screening methodologies, all developed by and large in the biotechnology and pharmaceutical sector, biochemists and cell biologists in academe are turning in earnest to small molecule screening as a fresh approach to discovering molecular probes of systems under their study. With the freedom to innovate and publish, academic screeners will now surely be in a position to return the favor to their private-sector colleagues with new discoveries and new approaches. It is clearly fitting that the Society for Biomolecular Screening (SBS), founded by private-sector researchers, has taken steps to welcome screeners from academe with the formation of the Academic Outreach Committee in the spring of 2003. The committee is composed of a mix of individuals from industry and academe, including myself, who have a keen interest in building bridges among academic screeners and their colleagues in pharmaceutical, biotechnology, and instrumentation companies. The committee also has the mandate of furthering the interests and profile of academic screeners in the SBS and has the potential to function as a nucleus for the exchange of ideas and experiences among academic screeners.
Our own HTS lab was founded by 3 principal investigators at McMaster whose research interests include antimicrobial research (Gerry Wright and I) and materials science (John Brennan). The genesis and funding for the laboratory came as part of a provincewide initiative in genomics and included close partnerships with combinatorial chemistry laboratories at York University and the University of Toronto. The thinking was that the chemists and screeners could work together, for example, in lead optimization activities. Indeed, the practicality of attracting the interest of collaborators in synthetic chemistry for downstream optimization of hits from commercial libraries is frequently a concern among academic researchers considering screening projects. In practice, we have been very pleasantly surprised by the interest of colleagues in synthetic chemistry and the ease with which meaningful collaborations have arisen.
Among the primary considerations in setting up the McMaster HTS Laboratory was to clearly define our goals. We wanted to establish a facility that would be in a position to lead in academic screening in Canada and elsewhere. Therefore, in addition to servicing the research needs of the principal investigators, the McMaster HTS Laboratory has aspired to provide a service to the biological research community in Canada and beyond. Those objectives have required the establishment of capable research, service, and training components that can be tapped into on an ad hoc basis. As a result, the McMaster HTS Laboratory has participated in collaborative projects with researchers from across the country and has been a resource, with advice and training, to researchers setting up screening operations in the public and private sectors in Canada and the United States.
In setting up the screening infrastructure, we needed to make some important philosophical choices. In screening circles, opinions on instrumentation, informatics, and compound collections border on religion, and having spent 3 years in the private sector in Boston, working in antibacterial lead discovery, I developed some strong thoughts of my own. Nonetheless, we consulted widely with colleagues in the private sector and visited screening labs in pharmaceutical companies in Montreal and Boston. Those consultations were invaluable, and our most important philosophical decision was to concentrate on the biological research capabilities of our facility. That meant de-emphasizing the technology of screening and choosing "off-the-shelf" technology where possible. We have not, for example, allocated funds to programming, engineering, or instrumentation development, and we have not elected to push the limits of throughput. The result is a screening operation that is flexible, user-friendly, and small in scale and functions with a highly trained but skeleton crew of just 3 full-time researchers, including a lab manager and 2 research scientists.
Our compound collection is consistent with this user-friendly philosophy. The core of the collection is a couple of milligrams each of 50,000 diverse molecules from Maybridge, an organic compound producer in the United Kingdom. This collection is recognized in screening circles for its quality and for ease of resupply. The latter is particularly important to the academic biological screener who is typically without resources for resynthesis. In our experience, molecules can be reordered cost-effectively from Maybridge with quick turnaround to verify structure and activity and to make headway on the mechanism of action. These additional data are very helpful to solidifying downstream research activities and may provide preliminary results to secure funding and collaborations for those efforts. In addition to our core collection of 50,000 Maybridge compounds, we have lesser (µg) quantities of Chembridge molecules (50,000) and 10,000 proprietary molecules under agreement with Crompton Corporation. We have found that the core collection provides a good first pass that fits with most academic goals and finances, where the latter is a reality of academic research budgets, particularly due to the high costs of disposables in screening. For high-priority screens and targets, we screen our entire collection.
For our screening instrumentation, we chose an integrated screening system, the SAGIAN Core System from Beckman, equipped with a 3-meter rail, ORCA robotic arm, Biomek FX liquid handler (96-tip and span 8 pipettors), and SAMI integration software. For instrumentation on the rail, we have an LJL Analyst fluorescence reader, Molecular Devices Spectra Max plus absorbance reader, CO 2 incubator, and so forth, all components that Beckman had successfully integrated before with the SAMI software. The goal here was to create a system that worked with little development or fiddling. In addition to the integrated SAGIAN Core System, we also have a complement of offline readers and instrumentation, including a Biomek FX liquid handler equipped with a single-pod 96-tip pipettor/gripper that is frequently used for plate replication and as general liquid-handling capacity to assuage the screening queue.
For informatics, we have likewise chosen off-the-shelf solutions with ActivityBase by IDBS and DecisionSite by Spotfire. Again, the goal was to streamline our operation with little or no informatics development. Here, ActivityBase is a highly functional relational database system, and DecisionSite serves as a data visualization and analysis tool. Together, these programs have been particularly up to the service challenges of the McMaster HTS Laboratory, where meaningful data and queries must be delivered to users not trained on the software.
The McMaster HTS Laboratory became fully operational in April 2002. Since that time, despite our off-the-shelf approach, we have experienced delays and downtime amounting to about 20% due to instrumentation, informatics, and user difficulties. Even so, the growing pains appear to be behind us now. To date, we have collected some 8 million data points on 5 completed screening campaigns and 4 screens that are at various stages of completion. Although the first 5 screens were from the laboratories of the principal investigators here at McMaster, the lion's share of those under way are screens for researchers from other institutions across Canada. Of the assays completed, 1 was cell based and 4 were biochemical, including 1 on dihydrofolate reductase that has recently been published. 1 All of the screens have produced molecules worthy of ongoing study and have spurred significant collaborations with synthetic chemists and structural biologists. Among the most important lessons learned: devote quality time to assay development and run screens in duplicate.
In closing, it is a great time to be a small molecule screener in academe. Thanks mostly to more than a decade of development directed by the pharmaceutical and biotechnology sectors, screening technology is now available in sophisticated and user-friendly solutions. Furthermore, thanks to organizations such as the SBS and its Journal of Biomolecular Screening, the approaches and methodologies are maturing and becoming more accessible to publicdomain researchers. Establishing a reasonable-scale screening lab-oratory, however, remains a complex undertaking requiring investment and strategies for operation that are uncommon among facilities traditionally used by academic researchers. Regardless of the challenges, small molecule screening is very likely to find an enduring home in academe as biologists in universities and research institutes are increasingly recognizing the utility of small molecules as probes of their experimental systems.
